STOCK TITAN

Day One Biopharmaceuticals Inc - DAWN STOCK NEWS

Welcome to our dedicated news page for Day One Biopharmaceuticals (Ticker: DAWN), a resource for investors and traders seeking the latest updates and insights on Day One Biopharmaceuticals.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Day One Biopharmaceuticals's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Day One Biopharmaceuticals's position in the market.

Rhea-AI Summary
Day One Biopharmaceuticals announces positive results from FIREFLY-1 trial, with an overall response rate (ORR) of 67% and clinical benefit rate (CBR) of 93% in patients with relapsed or progressive pediatric low-grade glioma (pLGG). The company has initiated the rolling submission of the tovorafenib New Drug Application (NDA) and expects to complete it by October 2023. Day One also completed a $172.5 million public offering, strengthening their balance sheet.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.66%
Tags
-
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.28%
Tags
-
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.28%
Tags
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.61%
Tags
conferences
-
Rhea-AI Summary
Day One Biopharmaceuticals announces first quarter 2023 financial results and recent corporate achievements
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
16.69%
Tags
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
8.18%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.27%
Tags
conferences
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
7.46%
Tags
Day One Biopharmaceuticals Inc

Nasdaq:DAWN

DAWN Rankings

DAWN Stock Data

1.20B
54.60M
19.7%
89.21%
10.28%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
US
San Francisco

About DAWN

day one biopharmaceuticals understands that advances in cancer research now enable drug developers to identify children and adults who may benefit from the same medicine. we are a unique company created to find and develop new therapies that meet the critical needs of people of all ages living with cancer – starting from the biology of childhood cancer. our distinctive approach, together with our trusted network of pediatric oncology investigators, gives us an unparalleled ability to advance promising discoveries for patients of any age. we are ready to pursue the full potential of our therapies to improve the greatest number of lives as quickly as possible.